Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
U.S. Centers for Disease Control and Prevention
Headquarters: Atlanta, GA, United States of America
Website: http://www.cdc.gov
Year Founded: 1946
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Feb 20, 2025
Politics, Policy & Law
CDC vaccine meeting postponement raises red flags
Concerns mount that Trump administration vaccine policies will harm public health, disincentivize vaccine R&D
BioCentury | Feb 12, 2025
Politics, Policy & Law
Courts impose limits on disruption of public health, science
Judges have ordered FDA, CDC webpages restored, blocked drastic NIH funding cuts and will be asked to overturn back-to-office orders
BioCentury | Jan 25, 2025
Editor's Commentary
Whirlwind hits FDA, NIH: a Perspective
The first week of Trump 2.0 has been eventful, writes Washington Editor Steve Usdin
BioCentury | Aug 23, 2023
Distillery Therapeutics
A single-dose intranasal VRP vaccine for Nipah virus
BioCentury | Sep 14, 2022
Finance
Sept. 13 Quick Takes: Acelyrin heads for Phase III with $300M round
Plus note deals for Alnylam, Sarepta and updates from Rubius, Relay, Forge, Owkin, Ori and more
BioCentury | Sep 2, 2022
Politics, Policy & Law
Sept. 1 Quick Takes: setback for FTC over Illumina’s Grail acquisition
Plus CDC recommends BA.4/BA.5 updated boosters, and updates from CHMP, Y-mAbs and more
BioCentury | Jun 24, 2022
Regulation
June 23 Quick Takes: FDA unveils neurogenerative disease action plan
Plus FDA places hold on Sarepta DMD trial and updates from Novartis, uniQure, DermBiont, Valneva and more
BioCentury | Mar 2, 2022
Management Tracks
Former CDC Director Gerberding to lead FNIH
Merck executive brings deep experience with infectious disease, patient engagement and public health emergencies to the non-profit
BioCentury | Dec 17, 2021
Finance
Dec. 16 Quick Takes: Syncona’s Anaveon raising mega-round for IL-2 agonists
Plus: Biogen readies confirmatory trial of Aduhelm, Senate passes ALS bill and updates from NIH, Regeneron, Horizon-Alpine and more
BioCentury | Nov 11, 2020
Product Development
Medicare co-pays for COVID-19 mAbs scrapped, bamlanivimab distribution begins
The Trump administration has found a way to eliminate out-of-pocket costs for Medicare beneficiaries who receive COVID-19 mAbs, removing a potential barrier to treatment. The announcement came a day
Items per page:
1 - 10 of 161